Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 2002
Business Overview: Bio-Rad manufactures and supplies products and systems for life science research, healthcare, analytical chemistry, and other markets, focusing on separating, identifying, analyzing, and purifying chemical and biological materials.
Key Financial Metrics
| Metric (in thousands) | Q3 2002 | Q3 2001 | 9M 2002 | 9M 2001 |
|---|---|---|---|---|
| Net Sales | $224,878 | $186,104 | $649,720 | $584,126 |
| Gross Profit | $129,026 | $104,747 | $372,640 | $322,938 |
| Gross Margin % | 57.4% | 56.3% | 57.4% | 55.3% |
| Net Income | $16,617 | $7,047 | $51,622 | $27,177 |
| Diluted EPS | $0.64 | $0.28 | $1.99 | $1.07 |
| Operating Cash Flow (9M) | $70,150 (2002) vs $59,083 (2001) | |||
| Cash & Equivalents (End of Period) | $39,250 | |||
| Total Debt (Current + Long-term) | $149,509 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21% in Q3 2002 and 11.2% for the nine-month period compared to 2001. Growth was driven by the Life Science segment (BSE tests, proteomics) and Clinical Diagnostics (quality controls, autoimmune, diabetes). Currency translation (weaker USD) contributed approximately 4% to Q3 sales growth.
- Profitability: Net income more than doubled in Q3 2002 ($16.6M vs $7.0M) and nearly doubled for the nine-month period ($51.6M vs $27.2M). Gross margins improved due to a favorable sales mix (higher consumables vs. equipment) and the divestiture of the lower-margin spectroscopy instrument line in late 2001.
- Expense Management: SG&A expenses as a percentage of sales decreased to 32.6% in Q3 2002 from 33.8% in Q3 2001. R&D expenses decreased slightly to 8.9% of sales in Q3 2002.
- Accounting Changes: The Company adopted SFAS No. 142 in 2002, ceasing the amortization of goodwill. This resulted in a pro forma increase to prior year net income if adjusted for the removal of goodwill amortization charges.
- Foreign Exchange: Foreign exchange losses increased significantly ($2.7M in Q3 2002 vs $1.5M in Q3 2001), primarily due to the devaluation of the Brazilian Real (approx. 25% vs USD in Q3, 60% YTD) and high hedging costs.
Guidance, Outlook, and Risks
- Debt Reduction: Management actively reduced leverage, repurchasing $10.0 million of Senior Subordinated debt in Q3 2002 and an additional $18.2 million subsequent to the quarter-end. Total outstanding Senior Subordinated debt was reduced to $140.0 million (par value) by quarter-end.
- Acquisitions: Acquired Virtek Biotech Inc.'s microarray and robotics business for approximately $7 million in June 2002. No goodwill was recorded. Management continues to review potential acquisitions but noted no material discussions beyond initial phases.
- Capital Expenditures: Net capital expenditures were $31.3 million for the nine months ended Sept 30, 2002. Construction began on a new $25 million facility for manufacturing and offices, expected to take 15 months to complete.
- Risks:
- Currency Exposure: Significant exposure to foreign currency fluctuations, particularly the Brazilian Real, which impacts both sales translation and hedging costs.
- Debt Servicing: The Company maintains substantial leverage and relies on access to capital markets to service debt.
- Regulatory & Competition: Risks related to government regulation in healthcare/life sciences and competition in product development.
- Unusual Items: Recorded a $2.0 million non-cash impairment charge in Q1 2002 for the investment in Digilab, LLC. No goodwill impairment was recorded in the first nine months of 2002.
Investor Verification Checklist
- Currency Impact: Verify the extent to which reported sales and margin growth are driven by the weakening U.S. dollar versus organic demand, particularly regarding the Brazilian subsidiary's performance.
- Debt Structure: Confirm the terms and remaining balance of the Senior Subordinated debt and the impact of recent repurchases on future interest expense.
- Inventory Levels: Review the $21.5 million increase in net inventories (YTD) to ensure it aligns with demand forecasts for consumables and new product launches, rather than obsolescence.
- Goodwill Accounting: Note that prior year comparisons for net income are affected by the cessation of goodwill amortization under SFAS No. 142; review pro forma adjustments for accurate trend analysis.
- Segment Performance: Analyze the specific contribution of the Life Science segment (BSE tests) to overall growth, as this may be a cyclical or event-driven demand factor.